18-Jun-2020 - CureVac AG

CureVac Receives Regulatory Approval to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

Trial will start promptly and will be conducted in Germany and Belgium

CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium. First subjects will be vaccinated at the Institute for Tropical Medicine in Tübingen and the Ghent University Hospital (Belgium), the Tropical Institute of the University Hospital Munich, LMU (Germany), and the Hannover Medical School (Germany).

CureVac´s mRNA vaccine candidate utilizes nucleotides without chemical modifications in the mRNA and is designed to provide a strong and balanced activation of the immune system. The mRNA encodes the full-length spike protein of SARS-CoV-2 and is formulated with lipid nanoparticles (LNP).

The vaccine project began in early 2020 and initially focused on characterization of several potential candidates that then led to the selection of the final candidate, termed CVnCoV. This thorough selection process was based on humoral and cellular immunogenicity data, a balanced immune-response as well as speed and capability for large scale manufacturing.

The Phase 1 dose escalation clinical trial will include 168 healthy subjects between the ages of 18 to 60 and will target a dose range of 2 µg to 8 µg. Aim is to determine the optimal dose as well as to evaluate the safety and immune profile of the vaccine in humans.

“We are encouraged that we received green light from the regulatory authorities to start the clinical development of our COVID-19 candidate. During the last few months our team has put a lot of efforts into the preclinical validation of several vaccine candidates to select an optimal construct. We are confident that our early optimization work will provide a safe and effective low dose vaccine. In parallel, we are already producing large quantities of this trial medication under GMP conditions,” says acting CEO of CureVac, Dr. Franz-Werner Haas.

Dr. Mariola Fotin-Mleczek, CureVac Chief Technology Officer, adds: “We are convinced that we are on the right track with our SARS-CoV-2 vaccine candidate. The data we generated in various animal models indicated that the vaccine candidate induces high virus neutralizing antibody titers compared to sera from patients who recovered from COVID-19 disease. Immune response induced by our vaccine candidate was well balanced and included the generation of spike protein specific T cell responses. We now look forward to confirm these results in humans.“
CureVac has received financial support for its COVID-19 vaccine development from the Coalition for Epidemic Preparedness Innovations (CEPI).

Facts, background information, dossiers
More about CureVac
  • News

    CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer

    CureVac announced that Dr. Franz-Werner Haas, previously acting Chief Executive Officer and Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO). Before Dr. Haas joined CureVac in June 2012, he worked as Vice President Operations and Chief Compliance Officer of SY ... more

    CureVac Raises a Total of USD 640 Million in Private Financing Round

    CureVac AG announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and ... more

    GSK and CureVac announce strategic mRNA technology collaboration

    GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration comple ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more